Area of research
Hematology · Genetics
Research interest
Research interests include Acute Myeloid Leukemia Research, Chronic Myeloid Leukemia Treatments, Myeloproliferative Neoplasms: Diagnosis and Treatment, and Hematopoietic Stem Cell Transplantation.
Assessing AML-based risk criteria in patients with accelerated/blast-phase MPN treated with less-intensive therapy
Response and outcomes of patients with IDH1/2- mutated accelerated/blast-phase myeloproliferative neoplasms
Mechanisms of immune escape and extramedullary tropism in leukemia cutis
American Society of Hematology 2025 guidelines for treating newly diagnosed acute myeloid leukemia in older adults
Early persistence of recipient stem-cells and T-cell dysregulation are associated with relapse after transplant in AML/MDS
Long‐term follow‐up of <scp>VIALE‐A</scp>: Venetoclax and azacitidine in chemotherapy‐ineligible untreated acute myeloid leukemia
A Phase 1 First-in-Human Study of the MCL-1 Inhibitor AZD5991 in Patients with Relapsed/Refractory Hematologic Malignancies
Integrative genotyping of cancer and immune phenotypes by long-read sequencing
Efficacy and safety of venetoclax plus azacitidine for patients with treatment-naive high-risk myelodysplastic syndromes
Treatment approach and outcomes of patients with accelerated/blast-phase myeloproliferative neoplasms in the current era
Asciminib plus dasatinib and prednisone for Philadelphia chromosome–positive acute leukemia
Proposals for revised International Working Group–European LeukemiaNet criteria for anemia response in myelofibrosis
A multidimensional analysis reveals distinct immune phenotypes and the composition of immune aggregates in pediatric acute myeloid leukemia
Advancing drug development in myelodysplastic syndromes
Tracking Rare Single Donor and Recipient Immune and Leukemia Cells after Allogeneic Hematopoietic Cell Transplantation Using Mitochondrial DNA Mutations
Consensus proposal for revised International Working Group response criteria for higher risk myelodysplastic syndromes
Mechanisms of response and resistance to combined decitabine and ipilimumab for advanced myeloid disease
Venetoclax and idasanutlin in relapsed/refractory AML: a nonrandomized, open-label phase 1b trial
Impact of <i>F</i> <i>LT3</i> Mutation on Outcomes after Venetoclax and Azacitidine for Patients with Treatment-Naïve Acute Myeloid Leukemia
A phase 1b study of venetoclax and azacitidine combination in patients with relapsed or refractory myelodysplastic syndromes
Defining disease modification in myelofibrosis in the era of targeted therapy
Addition of navitoclax to ongoing ruxolitinib treatment in patients with myelofibrosis (REFINE): a post-hoc analysis of molecular biomarkers in a phase 2 study
Long-Term Follow-up of the Phase 3 Viale-a Clinical Trial of Venetoclax Plus Azacitidine for Patients with Untreated Acute Myeloid Leukemia Ineligible for Intensive Chemotherapy
Measurable Residual Disease Response and Prognosis in Treatment-Naïve Acute Myeloid Leukemia With Venetoclax and Azacitidine
Racial and ethnic enrollment disparities and demographic reporting requirements in acute leukemia clinical trials
Molecular Responses Are Observed across Mutational Spectrum in Treatment-Naïve Higher-Risk Myelodysplastic Syndrome Patients Treated with Venetoclax Plus Azacitidine
Venetoclax and Azacitidine in the Treatment of Patients with Relapsed/Refractory Myelodysplastic Syndrome
Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia
Reduced Mitochondrial Apoptotic Priming Drives Resistance to BH3 Mimetics in Acute Myeloid Leukemia
Safety, Efficacy, and Patient-Reported Outcomes of Venetoclax in Combination with Azacitidine for the Treatment of Patients with Higher-Risk Myelodysplastic Syndrome: A Phase 1b Study